CDMO, CMO, Supplier Roundup in Supporting COVID-19 Projects
The latest from CDMOs/CMOs and suppliers in COVID-19 projects featuring Lonza and BioCentriq.
Biologics Manufacturing
Lonza, Altimmune Expand Mfg Pact for COVID-19 Vaccine
Lonza and Altimmune, a Gaithersburg, Maryland-based clinical-stage biopharmaceutical company, have expanded their manufacturing pact for AdCOVID, Altimmune’s single-dose intranasal vaccine candidate for COVID-19.
Under the expanded agreement, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID at its facility near Houston, Texas. The manufacturing agreement was first announced in November 2020. Altimmune recently began a Phase I clinical trial and anticipates having a data readout in the second quarter of 2021.
Source: Lonza, Altimmune (manufacturing), and Altimmune (results)
Tevogen Bio, BioCentriq in Pact for T-cell Therapy for COVID-19
Tevogen Bio, a Metuchen, New Jersey-based clinical-stage biotechnology company, and BioCentriq, a Newark, New Jersey-based CDMO for cell- and gene-therapy process development and clinical manufacturing, have entered into a partnership to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment.
Under the partnership, BioCentriq’s facilities will be used to produce Tevogen’s proprietary COVID-19 targeted T cells. The teams will use the processes and technology required in the large-scale manufacturing of Tevogen’s clinical-grade, allogeneic T-cell therapy. BioCentriq has a GMP clinical manufacturing facility in Newark, New Jersey and a pilot plant in South Brunswick, New Jersey.
Tevogen’s investigational new drug (IND) application for its proprietary antigen-specific T cell therapy is currently under review by the US Food and Drug Administration. In the upcoming trials, Tevogen will study its COVID-19-specific CD8+ T cells, TVGN-489, for the drug’s safety and ability to recognize and eliminate COVID-19-infected cells.
Source: Tevogen Bio and BioCentriq
